T-Series
T-Series

Price range: £29.99 through £134.99

Add to basket This product has multiple variants. The options may be chosen on the product page

T-Series

Price range: £29.99 through £134.99

  • UK Stock
  • Secure Payments
  • Discreet UK Delivery

A dual GIP and GLP-1 receptor agonist, supplied as a lyophilised material for metabolic-signalling research.

COMPLETE YOUR KIT

Bacteriostatic Water - 3ml
Bacteriostatic Water - 3ml

In stock

£3.99
GHK-Cu - 50mg
GHK-Cu - 50mg

In stock

£19.99
1 Vial
£29.99
1 Vial
£26.99 Save 10%
3 Vials
£25.49 Save 15%
5 Vials
£23.99 Save 20%

For in vitro laboratory research only.
Not for human or veterinary use. Not for diagnosis, treatment, cure, or prevention of any disease. No dosage, administration, or injection guidance is provided.

A 39-amino-acid peptide studied for dual activity at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is supplied as a lyophilised research material for controlled laboratory and analytical work only.

Research material only

This material is not supplied as a licensed medicine, treatment, supplement or consumer product. It is not for human or veterinary use, consumption or administration, and is not intended to diagnose, treat, cure or prevent any disease.

Compound overview

CompoundT
Development codeLY3298176
Research classDual GIP / GLP-1 receptor agonist
Reference molecular massApproximately 4,813 Da
FormLyophilised material

Research context

Published research describes this as a single-molecule dual GIP and GLP-1 receptor agonist. It has been investigated in studies of incretin signalling and the interaction between GIP and GLP-1 receptor pathways. References to published studies describe the compound investigated by those authors; they do not establish the identity, performance or suitability of any material sold on this page.

Batch documentation

Independent analytical documentation is published where available for specific batches and variations. A result indicator appears only when a published record is available. Match the vial size and batch identifier to the corresponding report before relying on any result.

View available T-Series lab results →

Supply and laboratory handling

  • Supplied in the vial size selected above.
  • Keep the sealed lyophilised vial dry and protected from direct light.
  • A cool, dry place, refrigerator or freezer may be used according to the intended storage duration, compound-specific information and your laboratory’s validated procedure.
  • Use clean laboratory technique and equipment appropriate to the intended analytical method.
  • Follow the lot-specific documentation and your laboratory’s validated handling and storage procedures.
  • Avoid repeated temperature cycling and unnecessary exposure to moisture.

Where a batch document or supplier specification gives different instructions, the lot-specific document takes precedence.

Frequently asked questions

What is T-Series?

Known by the development code LY3298176, it is a peptide described in the scientific literature as a dual agonist at the GIP and GLP-1 receptors.

Is T-Series supplied as a medicine?

No. This material is supplied solely for controlled laboratory research. It is not supplied as a medicine, treatment, supplement or consumer product.

Which vial sizes are available?

Current vial sizes, stock, pre-order status, pricing and any batch-documentation indicators are shown in the variation selector above.

Does every vial size have a published laboratory result?

No. Results are available only for the selected batches and vial sizes marked with a result indicator. Always check the batch identifier on the report.

How should the material be stored?

Keep the sealed lyophilised material dry and protected from light. A cool, dry place, refrigerator or freezer may be used according to the intended storage duration, compound-specific information and your laboratory’s validated procedure. Avoid repeated temperature cycling and moisture exposure. No universal shelf-life is stated unless it is supported by batch documentation.

Information reviewed: 29 August 2026.

Size

10mg, 20mg, 30mg, 40mg, 60mg, 100mg

Batch-specific analytical documentation

Independent analytical results are published for selected Havoc Labs products, vial sizes and batches. The result attached to one variation must not be treated as evidence for a different size or batch.

  • Result available: a published report is available for the marked variation.
  • Test pending: a sample has been submitted, but no completed result is being claimed.
  • No indicator: no product-specific result is currently displayed for that variation.

Check the identifiers

Always match the compound, vial size and batch reference on the product to the corresponding laboratory record. Where the laboratory provides an independent verification facility, use it to confirm the report.

Browse published lab results →

Storage and stability

Storage requirements can vary by compound, physical form, intended storage duration and batch. Follow the lot-specific documentation and your laboratory’s validated procedure wherever these are available.

Form Suggested storage Important note
Sealed lyophilised material Keep in a cool, dry place, refrigerated at 2–8°C or frozen, as appropriate for the compound and intended storage period. Keep sealed, dry and protected from direct light. Follow compound- and batch-specific documentation and avoid repeated temperature cycling.
Reconstituted solution Refrigerate at 2–8°C unless the applicable laboratory protocol specifies otherwise. Stability depends on the preparation conditions, solvent, concentration, container and handling. No universal storage period is claimed.

No universal shelf-life is claimed

Do not assume a fixed expiry or prepared-solution storage period unless it is supported by relevant stability data or batch documentation. Where a lot-specific document gives different instructions, that document takes precedence.

Published research

The sources below concern tirzepatide (LY3298176) as investigated by their respective authors. They are provided for scientific context and do not establish the identity, purity, performance or suitability of any Havoc Labs batch.

  1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). The Lancet, 2021. View on PubMed ↗
  2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022. View on PubMed ↗
  3. ClinicalTrials.gov. SURMOUNT-1 study record NCT04184622, including study design and protocol information for LY3298176. View trial record ↗
  4. PubChem. Tirzepatide compound record CID 156588324, containing reference identifiers and structural information. View compound record ↗

Literature is not batch evidence

Published findings relate to the materials, participants and conditions used by the cited researchers. Assess any available Havoc Labs batch documentation separately.